New era for ME/CFS research as top cytokine study attracts media headlines
The immune systems of patients who have recently developed ME/CFS look markedly different from those who have been ill for much longer, according to a major new study from Drs. Ian Lipkin and Mady Hornig at Columbia University. This shift in immune function hadn’t been seen before.
Discuss the article on the Forums.

(US) Contact Your Federal Legislator and Make Your Voice Heard about Specialty Tiers!

Discussion in 'Action Alerts and Advocacy' started by ggingues, Apr 18, 2012.

  1. ggingues

    ggingues $10 gift code at iHerb GAS343 of $40

    Concord, NH
    Advocacy Call to Action:
    A number of health insurance companies throughout

    the country are adopting a new specialty tier pricing system for expensive drugs, requiring patients to pay much more for life-saving and disease-stabilizing medications. Insurers are abandoning the traditional arrangement where patients pay a fixed co-pay amount and instead charging patients a percentage of the cost of certain high-priced drugs, usually 25 to 33 percent, which can amount to thousands of dollars a month for vital medications.

    The Patients' Access to Treatments Act of 2012 (H.R. 4209) was introduced in March by US House of Representatives David McKinley (R-WV) and Lois Capps (D-CA) to address this important issue. H.R. 4209 requires health insurers to place specialty drugs within the same classification as Tier III non-preferred drugs. It would allow people living with serious devastating health conditions to continue to have access to the critical treatments which they need in order to live active and productive lives.

    Click here to find your House Representative

    Read the complete article and available template letter.

See more popular forum discussions.

Share This Page